LipoCurc (liposomal curcumin) / Signpath Pharma - LARVOL DELTA

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: University Health Network, Toronto | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology

Phase I/II study of liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas. (ASCO 2026) - P1/2 | "LC combined with standard chemoradiation was safe and well tolerated, with encouraging exploratory signals of disease control in newly diagnosed glioblastoma. Further evaluation in an expanded Phase II/III study is planned."

Clinical • Combination therapy • P1/2 data • Brain Cancer • Cardiovascular • CNS Disorders • Epilepsy • Glioblastoma • Glioma • Hematological Disorders • High Grade Glioma • Solid Tumor • Thrombocytopenia • MGMT

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: University Health Network, Toronto

New P1 trial • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology

Curcumin as a palliative treatment for malignant pleural effusion (ANZCTR) - P1 | N=9 | Withdrawn | Sponsor: Flinders University | Recruiting ➔ Withdrawn

Trial withdrawal • Palliative care • Respiratory Diseases

A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer (clinicaltrials.gov) - P1/2 | N=30 | Completed | Sponsor: SignPath Pharma, Inc. | Active, not recruiting ➔ Completed

Trial completion • Oncology

Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin: curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE). (PubMed, BMJ Open) - "Participants will be administered a single dose of liposomal curcumin (LipoCurc, SignPath Pharma) via their existing TIPC as a sequential enrolling case series with the following dose cohorts: 100, 200 and 300 mg/m...ACTRN12620001216909. V.1.0."

Clinical • Journal • P1 data • Pleural effusion • Oncology • Palliative care • Respiratory Diseases • Thoracic Cancer